We read with great interest “Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis” by Ramanathan et al. and appreciate their diligent work and their conclusion to offer extracorporeal membrane oxygenation (ECMO) therapy to carefully selected patients presenting with severe acute respiratory distress syndrome (ARDS) related to COVID-19 . However, the relatively low calculated mortality of 37.1% caught our attention.
While reviewing the input data in detail, we noticed two discrepancies...
- xtracorporeal membrane oxygenation (ECMO)
- acute respiratory distress syndrome (ARDS)